Int J Sports Med 2006; 27(11): 880-884
DOI: 10.1055/s-2006-923862
Physiology & Biochemistry

© Georg Thieme Verlag KG Stuttgart · New York

ACTN3 Genotype in Professional Endurance Cyclists

A. Lucia1 , F. Gómez-Gallego1 , C. Santiago1 , F. Bandrés1 , C. Earnest2 , M. Rabadán3 , J. M. Alonso4 , J. Hoyos5 , A. Córdova6 , G. Villa7 , C. Foster8
  • 1European University of Madrid, Madrid, Spain
  • 2Cooper Institute Center for Human Performance and Nutrition Research, Dallas, TX, USA
  • 3Department of Physiology, Sport Medicine Center, Higher Sports Council, Madrid, Spain
  • 4Medical Department, Spanish Track and Field Federation, Madrid, Spain
  • 5Professional cycling team Isles Baleares, Baleares, Spain
  • 6Department of Biochemistry and Physiology, University of Valladolid, Soria, Spain
  • 7Departamento de Physical Education, University of León, León, Spain
  • 8Department of Exercise and Sport Science, University of Wisconsin-La Crosse, La Crosse, WI, USA
Weitere Informationen

Publikationsverlauf

Accepted after revision: December 1, 2005

Publikationsdatum:
11. April 2006 (online)

Preview

Abstract

The Z-disk protein α-actinin-3 is only expressed in type II muscle fibres, which are responsible for generating forceful contractions at high velocity. Despite the evolutionary conservation of α-actinin-3, approximately one in every five Caucasians of European ancestry is totally deficient in this protein, due to homozygosity for a R577X polymorphism in the ACTN3 gene. This, together with the results of recent research on elite athletes, suggests that the “null” XX polymorphism might confer some advantage to endurance performance events. To test this hypothesis, we studied the frequency distribution of R577X genotypes in a group of 50 top-level male professional cyclists (26.9 ± 0.4 yrs [mean ± SEM]; V·O2max: 73.5 ± 0.8 ml · kg-1 · min-1). Their results were compared with those of a group of 52 Olympic-class male endurance runners (26.8 ± 0.6 yrs; V·O2max: 73.3 ± 0.8 ml · kg-1 · min-1) and 123 healthy, sedentary male controls. All subjects were Caucasian, and of European ancestry. No significant differences (p > 0.05) were found between groups: RR: 28.5 %; RX: 53.6 % and XX: 17.9 % in controls; RR: 28.0 %; RX: 46.0 % and XX: 26.0 % in cyclists; and RR: 25.0 %; RX: 57.7 %; XX: 17.3 % in runners). No differences were found in indices of endurance performance (VO2peak or ventilatory thresholds) between athlete carriers of each R577X genotype. In summary, although the α-actinin-3 deficient XX genotype may be detrimental for sprint performance in humans, the R577X polymorphism of the ACTN3 gene does not appear to confer an advantage on the ability of male athletes to sustain extreme endurance performance.

References

MD PhD Alejandro Lucía

European University of Madrid

Villaviciosa de Odón

28670 Madrid

Spain

Fax: 34 91 616 82 65

eMail: alejandro.lucia@uem.es